Plasma L-aspartic acid as a causal biomarker and modifier in gastric cancer risk and prevention. (IMAGE)

China Anti-Cancer Association

Plasma L-aspartic acid as a causal biomarker and modifier in gastric cancer risk and prevention.

Caption

Part I involves an observational case-control study to identify plasma metabolites associated with gastric cancer risk using the UGCED program. Part II outlines bi-directional two-sample MR analyses utilizing genetic susceptibility of metabolites and gastric cancer risk as IVs to explore causal relationships with data from UGCED, SIT, MITS, the UK Biobank, and the FinnGen project. Part III examines the interaction of genetically predicted plasma L-aspartic acid levels with H. pylori eradication, garlic supplementation, and vitamin supplementation in modifying gastric cancer risk. The study highlights L-aspartic acid as a potential biomarker for gastric cancer risk stratification and optimized primary prevention. GWAS, genome-wide association study; Helicobacter pylori, H. pylori; IV, instrumental variable; MITS, Mass Intervention Trial in Linqu, Shandong province; MR, Mendelian randomization; SIT, Shandong Intervention Trial; UGCED, Upper Gastrointestinal Cancer Early Detection.

Credit

Cancer Biology & Medicine

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted.

License

CC BY-NC

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.